Total Payments
$983,741
2024 Payments
$165,023
Companies
39
Transactions
1,116
Medicare Patients
243
Medicare Billing
$56,462
Payment Breakdown by Category
Other$753,185 (76.6%)
Travel$134,658 (13.7%)
Consulting$72,789 (7.4%)
Food & Beverage$22,317 (2.3%)
Education$769.68 (0.1%)
Research$23.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $749,194 | 272 | 76.2% |
| Travel and Lodging | $134,658 | 385 | 13.7% |
| Consulting Fee | $72,789 | 31 | 7.4% |
| Food and Beverage | $22,317 | 410 | 2.3% |
| Honoraria | $3,426 | 2 | 0.3% |
| Education | $769.68 | 14 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $565.00 | 1 | 0.1% |
| Unspecified | $23.00 | 1 | 0.0% |
Payments by Type
General
$983,718
1,115 transactions
Research
$23.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $333,360 | 326 | $0 (2024) |
| Amgen Inc. | $215,418 | 224 | $0 (2024) |
| GENZYME CORPORATION | $107,495 | 101 | $0 (2024) |
| Celgene Corporation | $91,762 | 108 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $67,428 | 59 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $56,259 | 91 | $0 (2022) |
| Astellas Pharma US Inc | $28,482 | 38 | $0 (2022) |
| Millennium Pharmaceuticals, Inc. | $20,527 | 15 | $0 (2017) |
| ABBVIE INC. | $18,236 | 29 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $17,620 | 32 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $165,023 | 171 | Incyte Corporation ($123,625) |
| 2023 | $155,986 | 148 | Incyte Corporation ($133,565) |
| 2022 | $51,052 | 66 | Incyte Corporation ($44,387) |
| 2021 | $71,579 | 87 | Incyte Corporation ($31,363) |
| 2020 | $85,339 | 69 | Celgene Corporation ($40,233) |
| 2019 | $194,345 | 201 | GENZYME CORPORATION ($60,767) |
| 2018 | $138,201 | 171 | Amgen Inc. ($48,182) |
| 2017 | $122,216 | 203 | Amgen Inc. ($47,208) |
All Payment Transactions
1,116 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Incyte Corporation | NIKTIMVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $342.50 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,480.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/10/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,110.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/09/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/09/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $64.32 | General |
| Category: Hematology/Oncology | ||||||
| 12/07/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $393.51 | General |
| Category: Hematology/Oncology | ||||||
| 12/07/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $393.51 | General |
| Category: Hematology/Oncology | ||||||
| 12/07/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $247.47 | General |
| Category: Hematology/Oncology | ||||||
| 12/07/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $179.97 | General |
| Category: Hematology/Oncology | ||||||
| 12/07/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $63.51 | General |
| Category: Hematology/Oncology | ||||||
| 12/07/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $32.25 | General |
| Category: Hematology/Oncology | ||||||
| 12/07/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $30.96 | General |
| Category: Hematology/Oncology | ||||||
| 12/06/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $42.85 | General |
| Category: Hematology/Oncology | ||||||
| 12/05/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $16.36 | General |
| 11/26/2024 | Amgen Inc. | Blincyto (Biological) | Travel and Lodging | Cash or cash equivalent | $199.94 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Amgen Inc. | Blincyto (Biological) | Travel and Lodging | Cash or cash equivalent | $31.99 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Incyte Corporation | JAKAFI (Drug), MONJUVI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,850.00 | General |
| Category: Hematology/Oncology | ||||||
| 11/14/2024 | Incyte Corporation | MONJUVI (Drug), JAKAFI | Travel and Lodging | Cash or cash equivalent | $490.50 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Incyte Corporation | JAKAFI (Drug), MONJUVI | Travel and Lodging | Cash or cash equivalent | $221.26 | General |
| Category: Hematology/Oncology | ||||||
| 11/14/2024 | Incyte Corporation | JAKAFI (Drug), MONJUVI | Travel and Lodging | Cash or cash equivalent | $187.00 | General |
| Category: Hematology/Oncology | ||||||
| 11/14/2024 | Incyte Corporation | JAKAFI (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $89.16 | General |
| Category: Hematology/Oncology | ||||||
| 11/14/2024 | Incyte Corporation | JAKAFI (Drug), MONJUVI | Travel and Lodging | Cash or cash equivalent | $85.91 | General |
| Category: Hematology/Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 3 | 55 | 167 | $58,287 | $13,866 |
| 2020 | 9 | 188 | 524 | $166,589 | $42,597 |
Total Patients
243
Total Services
691
Medicare Billing
$56,462
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 119 | $35,821 | $8,819 | 24.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 18 | $10,890 | $2,772 | 25.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 18 | 30 | $11,576 | $2,275 | 19.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 30 | 253 | $80,960 | $21,240 | 26.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 20 | 31 | $19,282 | $5,089 | 26.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 30 | 52 | $17,056 | $4,073 | 23.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 15 | 69 | $15,318 | $3,923 | 25.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 18 | 18 | $11,376 | $2,546 | 22.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 22 | 42 | $9,492 | $2,302 | 24.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 24 | 25 | $8,169 | $2,082 | 25.5% |
| 99358 | Prolonged patient service without direct patient contact first hour | Office | 2020 | 14 | 14 | $4,756 | $1,284 | 27.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 15 | 20 | $180.00 | $57.70 | 32.1% |
About Dr. Shahram Mori, MD
Dr. Shahram Mori, MD is a Internal Medicine healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/20/2010. The National Provider Identifier (NPI) number assigned to this provider is 1891001400.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shahram Mori, MD has received a total of $983,741 in payments from pharmaceutical and medical device companies, with $165,023 received in 2024. These payments were reported across 1,116 transactions from 39 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($749,194).
As a Medicare-enrolled provider, Mori has provided services to 243 Medicare beneficiaries, totaling 691 services with total Medicare billing of $56,462. Data is available for 2 years (2020–2021), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology, Hematology & Oncology
- Location Orlando, FL
- Active Since 08/20/2010
- Last Updated 05/16/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1891001400
Products in Payments
- JAKAFI (Drug) $227,634
- MOZOBIL (Drug) $113,329
- MONJUVI (Drug) $104,614
- Kyprolis (Biological) $91,588
- NINLARO (Drug) $75,944
- Blincyto (Biological) $59,415
- VYXEOS (Drug) $46,688
- Revlimid (Drug) $39,548
- Kyprolis (Drug) $38,256
- XGEVA (Biological) $22,683
- INREBIC (Drug) $21,803
- XOSPATA (Drug) $20,453
- RYDAPT (Drug) $17,347
- Rezlidhia (Drug) $14,322
- Venclexta (Drug) $14,156
- ONUREG (Drug) $10,418
- Inrebic (Drug) $10,339
- ICLUSIG (Drug) $8,749
- Defitelio (Drug) $4,978
- Xospata (Drug) $3,273
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Orlando
Michel Velez, Md, MD
Internal Medicine — Payments: $837,815
Internal Medicine $837,815
Dr. Rushang Patel, M.d, Ph.d, M.D, PH.D
Internal Medicine — Payments: $347,712
Internal Medicine $347,712
Dr. Jason Korenblit, M.d, M.D
Internal Medicine — Payments: $294,920
Internal Medicine $294,920
Kwabena Ayesu, Md, MD
Internal Medicine — Payments: $265,751
Internal Medicine $265,751
Dennis Yang, Md, MD
Internal Medicine — Payments: $203,483
Internal Medicine $203,483
Sarina Amin, M.d, M.D
Internal Medicine — Payments: $144,865
Internal Medicine $144,865